PTGX (Protagonist Therapeutics) Change In Receivables : $-155.0 Mil (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Protagonist Therapeutics Change In Receivables?

Protagonist Therapeutics's change in receivables for the quarter that ended in Dec. 2024 was $-165.0 Mil. It means Protagonist Therapeutics's Accounts Receivable increased by $165.0 Mil from Sep. 2024 to Dec. 2024 .

Protagonist Therapeutics's change in receivables for the fiscal year that ended in Dec. 2024 was $-155.0 Mil. It means Protagonist Therapeutics's Accounts Receivable increased by $155.0 Mil from Dec. 2023 to Dec. 2024 .

Protagonist Therapeutics's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Protagonist Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2024 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Protagonist Therapeutics's liquidation value for the three months ended in Dec. 2024 was $349.5 Mil.

Protagonist Therapeutics Change In Receivables Historical Data

The historical data trend for Protagonist Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagonist Therapeutics Change In Receivables Chart

Protagonist Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

3.34

-0.92

4.24

-9.99

-155.00

Protagonist Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-10.00	-290.04	300.00	0.04	-165.00

Protagonist Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-155.0 Mil.

Protagonist Therapeutics (NAS:PTGX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Protagonist Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	170.638	*	91
=	0.00

2. In Ben Graham's calculation of liquidation value, Protagonist Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Protagonist Therapeutics's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	418.913	-	69.43	+	0.75 * 0	+	0.5 * 0
=	349.5

Protagonist Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Protagonist Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagonist Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagonist Therapeutics Inc (NAS:PTGX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

7707 Gateway Boulevard, Suite 140, Newark, CA, USA, 94560

Website

https://www.protagonist-inc.com

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Executives

William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Arturo Md Molina	officer: Chief Medical Officer	10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
Asif Ali	officer: Chief Financial Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Patel Dinesh V Ph D	director, officer: President and CEO	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Suneel Gupta	officer: Chief Development Officer	7707 GATEWAY BLVD., SUITE 140, NEWARK CA 94560
Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Lewis T Williams	director	C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Sarah A O'dowd	director	3185 LAURELVIEW COURT, FREMONT CA 94538
Harold E Selick	director
Bryan Giraudo	director	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
Donald A. Kalkofen	officer: Chief Financial Officer	7707 GATEWAY BOULEVARD, SUITE 140, NEWARK CA 94560
David Y Liu	officer: Chief Scientific Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035
Chaitan Phd Khosla	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard S Shame	officer: Chief Medical Officer	C/O PROTAGONIST THERAPEUTICS, INC., 521 COTTONWOOD DRIVE, SUITE 100, MILPITAS CA 95035